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Original Article
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Introduction
Body composition changes are a hallmark feature of 
Huntington’s disease [HD]1. Unintentional weight loss is 
considered a prominent and well-documented outcome 
in individuals affected by the disease2,3. Individuals with 
manifest and premanifest HD are observed to have reduced 
bone mineral density (BMD), fat mass and lean tissue mass4.
Previous studies have documented a link between body 
mass index (BMI) values and the clinical progression of HD. 
In particular, relatively high BMI values have been found to be 
a robust predictor of disease progression, associated with a 
lower rate of functional, motor and cognition deterioration2,5. 
These findings indicate that body composition has a 
significant modulatory role on the clinical trajectory of HD. 
However, the relationship between body composition metrics 
and neuropathology, particularly striatal volume loss6,7, is yet 
to be investigated.
The purpose of this exploratory study was to investigate, 
for the first time, associations between BMI and other body 
composition metrics, including lean tissue mass, fat mass 
and BMD and striatal pathology (caudate and putamen) in 
individuals with premanifest HD and healthy controls. Based 
on recent findings2, we hypothesised that greater BMI, fat 
Abstract
Objective: Changes in body composition are a common feature of Huntington’s disease (HD) and are associated with 
disease progression. However, whether these changes in body composition are associated with degeneration of the 
striatum is unknown. This study aimed to explore the associations between body composition metrics and striatal brain 
volume in individuals with premanifest HD and healthy controls. Methods: Twenty-one individuals with premanifest HD 
and 22 healthy controls participated in this cross-sectional study. Body composition metrics were measured via dual-
energy X-ray absorptiometry. Structural magnetic resonance imaging of subcortical structures of the brain was performed 
to evaluate striatal volume. Results: There were no significant differences in body composition metrics between the 
premanifest HD and healthy controls group. Striatal volume was significantly reduced in individuals with premanifest HD 
compared to healthy controls. A significant association between bone mineral density (BMD) and right putamen volume 
was also observed in individuals with premanifest HD. Conclusion: These findings show striatal degeneration is evident 
during the premanifest stages of HD and associated with BMD. Additional longitudinal studies are nevertheless needed to 
confirm these findings.
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mass, lean tissue mass and BMD values would be associated 




A cross-sectional design was used to examine the 
relationships between whole-body composition (whole-
body lean, fat and bone mass) and striatal volume (left 
and right caudate and putamen) using Dual-energy X-ray 
Absorptiometry (DXA) and Magnetic Resonance Imaging 
(MRI), respectively. All aspects of the study were performed 
in accordance with the Declaration of Helsinki. This study 
was approved by Edith Cowan University Human Research 
Ethics Committee (ID: 13145). All participants provided 
written (via signature) and informed consent prior to 
enrolment and participation. 
Participants
Forty-three participants (21 individuals with premanifest 
HD; 22 healthy age- and sex-matched controls) were 
recruited for the study. Individuals with premanifest HD 
were recruited from existing databases, HD clinics and 
media advertisements in Perth, Western Australia, clinically 
defined as cytosine-adenine-guanine (CAG) repeat length 
>39 and a diagnostic confidence score <2 on the Unified 
Huntington’s Disease Rating Scale Total Motor Score 
(UHDRS-TMS)8. Participants were excluded if they had 
known cardiovascular, immunological, endocrine, metabolic 
or sleep disorders, recent or ongoing substance abuse, or 
concomitant neurological conditions. CAG age product (CAP) 
and disease burden score (DBS) data are measures of genetic 
burden and are presented for premanifest HD participants 
in Table 1. CAP score was calculated by multiplying the 
age at study entry by a scaling of the CAG repeat length 
as follows: CAPS=(Age × (CAG-33.66))/432.3326. CAP 
scores <1, 1 and >1 indicate a 5-year diagnosis probability of 
<0.5, 0.5 and >0.5, respectively9. DBS was calculated using 
the method described by Penney et al.10. One participant 
contributed incomplete data and was excluded from all 
analyses, resulting in 21 participants with premanifest HD 
and 22 healthy controls.
Study procedures
Anthropometry
Height was assessed using a wall-mounted stadiometer 
(Model 222, Seca, Hamburg, DE) to the nearest 0.1 
centimetre (cm) in triplicate, with the average recorded. 
Weight was assessed using an electronic weight scale (AE 
Adams CPW Plus-200, Adam Equipment Inc., CT, USA) to the 
nearest 0.1 kilogram (kg). BMI was subsequently calculated 
for each participant as weight in kg, divided by height in 
metres squared (kg/m2). 
Dual-energy X-ray Absorptiometry (DXA)
Whole body lean tissue mass, lean mass index (LMI: lean 
tissue mass [kg]/(height [m])2), fat mass, fat percentage, 
trunk fat mass, estimated visceral adipose tissue mass11, 
fat mass index (FMI: fat mass [kg]/(height [m])2) and BMD 
were assessed using DXA (Hologic Discovery A, Waltham, 
MA, USA). Standardised and reliable body positioning and 
scanning procedures were applied for all scans12 whole body 
scan models separate the body into axial and appendicular 
regions, however there is a need for localised appendicular 
segmentation models to further examine regions of 
interest within the upper and lower extremities. Similarly, 
inconsistencies pertaining to patient positioning exist in the 
literature which influence measurement precision and analysis 
outcomes highlighting a need for standardised procedure. 
This paper provides standardised and reproducible: 1, shown 
to produce scan/re-scan coefficient of variations below 1% 
in our laboratory12,13 whole body scan models separate the 
body into axial and appendicular regions, however there is 
a need for localised appendicular segmentation models to 
further examine regions of interest within the upper and 
lower extremities. Similarly, inconsistencies pertaining to 
patient positioning exist in the literature which influence 
measurement precision and analysis outcomes highlighting 
a need for standardised procedure. This paper provides 
standardised and reproducible: 1. Daily spine, step and 
radiographic uniformity calibrations were undertaken in 
accordance with manufacturer specifications.
Magnetic Resonance Imaging (MRI)
T
1
-weighted structural images of the brain were 
acquired from each participant using a 3T MRI scanner 
(GE Healthcare Discovery MR750W, General Electric 
Company, NSW, Australia). Images were acquired with a 
24-channel head coil using an IR-SPGR sequence (TA=9 m 
59 s, TR=3 s, TE=3.1 ms, TI=400 ms, flip angle=11o, field of 
view=256 mm x 256 mm, image matrix=256 x 256, 1 mm3 
isotropic voxels). Acquired T
1
-weighted MRI images were 
automatically processed with the longitudinal processing 
pipeline available in FreeSurfer14. The FreeSurfer pipeline 
creates an unbiased within-subject template using robust 
registration14. Other processing steps such as skull stripping, 
Talairach transforms, atlas registration, and spherical 
surface maps and parcellations, were then initialised with 
information from the within-subject template14. Volume of 
subcortical structures, including the caudate and putamen, 
were extracted and used in statistical analyses.
Statistical analysis
Participant demographics, clinical characteristics, body 
composition and striatal volume metrics are reported as mean 
and standard deviation unless otherwise stated. Normality 
assumptions were assessed using the Shapiro-Wilk test. 
Differences between individuals with premanifest HD and 
healthy controls were evaluated using independent t-tests. 
M. Turner et al.: Association of striatal volume and body composition
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Table 1. Comparison of baseline characteristics between premanifest HD and healthy control groups.
Variable HD group (n=21) HC group (n=22) Difference [95% CI] p-value
Demographic Characteristics
    Age (years) 41.90 (11.69) 45.21 (10.90) -3.52 [-10.59; 3.54] 0.311
    Male, n (%) 8 (38.1) 8 (34.8) - 0.540
Clinical Characteristics
    CAGn 42.718 (2.88) N/A N/A N/A
    CAP score 0.89 (0.18) N/A N/A N/A
    DBS 300.062 (74.43) N/A N/A N/A
    UHDRS-TMS 4.93 (7.39) N/A N/A N/A
    DCL 0.43 (0.71) N/A N/A N/A
    TFC 13 (0) N/A N/A N/A
Body Composition Measures
    BMI (kg/m2) 27.02 (3.65) 26.10 (3.01) 0.91 [-1.14; 2.97] 0.186
    BMD (g cm2) 1.15 (0.11) 1.13 (0.10) 0.02 [-0.04; 0.08] 0.244
    BMD T-score (SD) -0.05 (1.02) 0.18 (1.14) -0.23 [-1.20; 0.73] 0.690
    BMD Z-score (SD) 0.41 (1.04) 0.15 (1.05) 0.25 [-0.51; 1.02] 0.250
    Fat mass (g) 25042.64 (7289.16) 23661.17 (5546.43) 1381.47 [-2595.95; 5358.89] 0.243
    Fat (%) 32.07 (7.34) 31.80 (6.18) 0.26 [-3.90; 4.44] 0.448
    Trunk fat (g) 11868.22 (5047.93) 10289.26 (2782.57) 1578.96 [-915.82; 4073.74] 0.104
    Est. VAT Mass (g) 474.09 (268.27) 371.17 (167.49) 102.22 [-34.82; 239.27] 0.069
    Est. VAT Volume (cm3) 473.60 (289.43) 402.09 (181.03) 71.51 [-76.41; 219.44] 0.167
    FMI 8.84 (2.69) 8.35 (1.97) 0.49 [-0.95; 1.94] 0.248
    LTM (g) 50772.71 (12270.92) 48759.23 (10300.05) 2013.48 [-4951.43; 8978.39] 0.281
    LMI 17.5 (2.39) 17.03 (2.35) 0.46 [-0.99; 1.92] 0.260
    Total mass (g) 78359.79 (16044.67) 74845.81 (12860.47) 3513.97 [-5420.61; 12448.55] 0.215
Neuroimaging Measures
    Caudate (L) 3009.59 (668.04) 3698.58 (555.93) -688.98 [-1066.78; 311.18] <0.001*
    Caudate (R) 3117.45 (610.46) 3841.97 (586.12) -724.51 [-1093.03; 356.00] <0.001*
    Putamen (L) 5324.96 (1270.40) 5842.08 (815.37) -517.11 [-1171.42; 137.19] 0.059
    Putamen (R) 5281.60 (1041.43) 5970.22 (715.85) -688.61 [-1236.75; 140.47] 0.007**
Note: HD, Huntington’s disease; HC, healthy control; CAGn, number of cytosine-adenine-guanine repeats; CAP score: CAG-Age Product Scaled score; DBS, disease burden score; UHDRS-TMS, 
Unified Huntington’s Disease Rating Scale-Total Motor Score; DCL, diagnostic confidence level; TFC, total functional capacity; BMI, body mass index; BMD, bone mineral density; Est. VAT Mass, 
estimated visceral adipose tissue mass; Est. VAT Volume, estimated visceral adipose tissue volume; FMI, fat mass index; LTM, lean tissue mass; LMI, lean mass index. * significant after correction 
for multiple comparisons, ** not significant after correction for multiple comparisons.
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Associations between body composition and striatal volume 
were assessed using Pearson’s correlation coefficients 
(r). Significance level was initially set at p<0.05 and then 
corrected for multiple comparisons using the Benjamini-
Hochberg procedure. Data analysis was performed using 
STATA 15 (Stata Corp, 4905 Lakeway Dr, TX). 
Results
Participant demographics and clinical characteristics
There were no significant differences for age or sex 
between individuals with premanifest HD and healthy controls 
(Table 1). 
Body composition 
Differences in body composition metrics between 
groups are presented in Table 1. No significant differences 
were observed for body composition metrics between the 
two groups.
Striatal volume
After correction for multiple comparisons significant 
differences in left caudate (p<0.001) and right caudate 
(p<0.001) volume were found between individuals with 
premanifest HD and healthy controls (Table 1). 
Associations between body composition and striatal 
volume
After correction for multiple comparisons, a positive 
and significant association was observed between 
BMD and right putamen volume (r=0.621; p=0.002) in 
individuals with premanifest HD (Table 2). Non-significant 
associations were observed between BMD, right caudate 
(r=0.483; p=0.026) and left putamen (r=0.530; p=0.013). 
An inverse non-significant correlation was also observed 
between fat percentage and right putamen volume 
(r=-0.446; p=0.042). No associations were observed 
between whole body and trunk fat mass, lean tissue mass, 
estimated visceral adipose tissue mass and total mass and 
striatal volume in individuals with premanifest HD. There 
were no associations between body composition measures 
and striatal volume in healthy controls.
Discussion
Loss of weight, BMD and muscle mass are well-documented 
features of HD and have been linked to the clinical progression 
of HD2,4,15. It is not yet known whether alterations in body 
composition are associated with neuropathological changes, 
particularly striatal volume loss, in individuals with HD. 
Accordingly, we investigated associations between body 
Figure 1. The association of bone mineral density (BMD) measured as g cm-2 with average caudate and putamen volume in 21 individuals 
with premanifest Huntington’s disease (HD) and 22 healthy controls. The brain images highlight the specific areas of focus, including left 
and right caudate and putamen.
M. Turner et al.: Association of striatal volume and body composition
composition metrics and striatal volume in individuals with premanifest HD relative 
to age- and sex- matched healthy controls. Contrary to our expectations, we found 
no evidence of differences in body composition variables between groups. However, a 
significant association between BMD and right putamen volume was observed.
Recent findings indicate that BMI is closely associated with the clinical trajectory 
of HD2,5. However, associations between BMI and other body composition parameters 
and neuropathology have not yet been investigated. Here, we investigated associations 
between body composition metrics and striatal pathology in individuals with HD. No 
significant associations were observed between BMI, fat mass or lean tissue mass 
and caudate and putamen volume. Significant associations were, however, observed 
between BMD and right putamen volume. To our knowledge, this is the first study to 
report an association between striatal pathology and bone mineral density in individuals 
with HD. While the nature of this relationship is not yet known, evidence from mouse 
models suggests that striatal pathology, particularly the loss of dopaminergic neurons, 
is associated with decreased osteogenic activity and bone mineral deposition16. Based 
on this preclinical data it is plausible that striatal degeneration mediates bone mineral 
density changes in individuals with HD. However, this is a tentative supposition, 
especially considering that no differences in body composition were observed 
between individuals with premanifest HD and healthy controls, which indicates a 
coincidental finding. It is likely that neuropathological changes, which arise early in 
the disease process, do not underlie changes in body composition. In accordance with 
this supposition, it is possible that lifestyle changes, including physical activity and 
336http://www.ismni.org
















r 0.063 -0.059 0.049 0.105 0.058 -0.100 0.102 0.028 0.028 -0.065 0.246 0.150 0.228
P-value 0.779 0.791 0.861 0.693 0.797 0.656 0.650 0.899 0.900 0.773 0.267 0.504 0.306
Caudate (R)
r 0.048 0.004 0.107 0.144 0.018 -0.158 0.048 -0.060 -0.060 -0.110 0.254 0.163 0.220
P-value 0.831 0.985 0.703 0.522 0.935 0.481 0.831 0.790 0.789 0.624 0.253 0.468 0.324
Putamen (L)
r 0.273 0.393 0.168 0.168 0.248 0.133 0.152 0.033 0.032 0.251 0.048 0.143 0.151
P-value 0.218 0.070 0.547 0.453 0.264 0.552 0.498 0.883 0.884 0.258 0.831 0.523 0.500
Putamen (R)
r 0.130 0.200 0.147 -0.020 0.169 0.132 0.077 -0.020 -0.021 0.166 -0.023 0.033 0.055
P-value 0.562 0.371 0.599 0.929 0.451 0.557 0.731 0.926 0.924 0.458 0.918 0.882 0.805
HD group
Caudate (L)
r 0.094 0.333 0.114 0.340 0.169 0.012 0.134 0.156 0.158 0.092 0.128 0.022 0.185
P-value 0.685 0.139 0.769 0.279 0.463 0.956 0.561 0.499 0.492 0.690 0.579 0.924 0.420
Caudate (R)
r 0.057 0.483 0.327 0.433 0.119 -0.102 0.146 0.231 0.226 -0.006 0.212 0.063 0.230
P-value 0.805 0.026** 0.389 0.159 0.607 0.659 0.526 0.313 0.323 0.977 0.355 0.785 0.314
Putamen (L)
r -0.092 0.530 0.491 0.509 -0.117 -0.326 -0.022 0.087 0.087 -0.234 0.243 0.084 0.149
P-value 0.689 0.013** 0.179 0.090 0.612 0.148 0.921 0.706 0.707 0.305 0.286 0.714 0.518
Putamen (R)
r -0.106 0.621 0.653 0.624 -0.198 -0.446 -0.067 0.117 0.130 -0.328 0.337 0.176 0.185
P-value 0.647 0.002* 0.056 0.030** 0.389 0.042** 0.770 0.610 0.572 0.146 0.135 0.443 0.420
HC, healthy control; HD, Huntington’s disease; BMI, body mass index; BMD, bone mineral density; ESTVATMASS, estimated visceral adipose tissue mass; ESTVATVolume, estimated visceral adipose 
tissue volume; FMI, fat mass index; LTM, lean tissue mass; LMI, lean mass index; *significant after correction for multiple comparisons; **not significant after correction for multiple comparisons.
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diet, as a result of the disease process may underpin body 
composition changes. This latter explanation nevertheless 
needs to be explored in future studies. 
Consistent with previous observations, we found evidence 
of significant striatal degeneration. This finding was not 
surprising given the close proximity of participants to 
estimated clinical onset (within 5 years) as indicated by 
the high CAP score. The findings align with early evidence 
by Penney et al.10, who noted a linear relationship between 
striatal damage and the product of age and the length of the 
CAG repeat.
Contrary to our hypothesis, we found no evidence of 
significant reductions in BMI, whole-body fat mass, whole-
body BMD or whole-body lean tissue mass in premanifest HD 
individuals when compared to healthy controls. These results 
indicate that changes in body composition and whole-body 
BMD may only occur in the later stages of the disease. These 
results contrast previous findings, where reduced BMI, BMD 
and lean tissue mass has been reported in individuals with 
manifest and premanifest HD1,4,15. An explanation for the lack 
of whole-body BMD differences between groups may be that 
differences in bone structural parameters caused by chronic 
disease are more evident in load bearing bones of the lower-
extremities compared to the bones of the upper-extremities17. 
Future research is needed to investigate the BMD differences 
in load bearing bone of the lower-extremities in individual 
with premanifest HD and healthy controls.
Several other explanations may account for the noted 
discrepancy in findings across studies, including differences 
in participant demographics, such as customary diet and 
habitual physical activity levels between studies, and/
or difference models of DXA scanners (Lunar vs. Hologic) 
between the present and previous studies1,18. However, the 
variance between DXA scanners is unlikely a key factor, as 
previous studies have demonstrated high reproducibility of 
body composition values across different DXA scanners19.
Several limitations need to be considered when 
interpreting our findings. The sample size in the present 
study was relatively small and may have limited our 
statistical power to detect between-group differences in 
body composition and bone mineral density. The study 
only investigated associations between body composition 
parameters and the integrity of striatal structures. It is 
possible that body composition parameters may have been 
associated with other neural structures, particularly as 
previous studies have noted links between greater cortical 
atrophy and higher BMI values and hypothalamic atrophy 
and bone loss in ApoE4 carriers and individuals with early 
Alzheimer’s disease, respectively20,21. The study was also 
cross-sectional in nature, as such it is unknown whether 
the observed association between BMD and right putamen 
volume would persist over time. Finally, individuals in this 
study were sampled from Perth, Western Australia. It is 
possible that geographical differences may have affected 
body composition metrics. Longitudinal studies with larger 
sample sizes across various locations are needed to more 
robustly evaluate body composition changes and their 
relationship with disease progression in individuals with HD. 
Despite these limitations, it is important to note that this 
is the first study to investigate associations between body 
composition metrics and striatal volume with the use of MRI 
and DXA in individuals with HD and healthy controls. Our 
findings nevertheless need to be confirmed and expanded 
on in larger observational trials. In particular, there is a 
fundamental need to evaluate the longitudinal trajectory of 
neuropathological and body composition changes and their 
respective relationships. There is also a need to evaluate 
whether changes in lifestyle throughout the disease are 
related to body composition changes.
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